QTRX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-10

• months ended June 30, 2026, respectively, and $30.0 million and $50.5 million for the three and six months ended June 30, 2025, respectively.

• We expect operating losses to continue in the remainder of 2026 as we incur costs related to the following:

• •making required earnout payments under the Emission, Inc. ("Emission") acquisition agreement, which are contingent upon certain performance milestones;

• To improve our commercial effectiveness, we have hired a new Chief Commercial Officer who has extensive life sciences and diagnostics business experience. Under this new leadership, we are reorganizing our commercial organization to product-based selling, adding additional experienced sales leadersh…

• We are also increasing our strategic focus on Alzheimer’s diagnostics, as reflected by our hiring of an experienced Senior Vice President, General Manager Diagnostics to oversee our diagnostics business and investing in laboratory infrastructure and targeted commercial programs.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• We expect operating losses to continue in 2026 as we incur costs related to the following:

• •strategically acquiring and integrating companies or technologies that may be complementary to our business;

• •making required earnout payments under the Emission, Inc. ("Emission") acquisition agreement, which are contingent upon completion of certain performance milestones;

• We are making targeted investments to improve commercial effectiveness, including adding experienced sales leadership within our Accelerator business, improving lead generation efforts, and investing in marketing spend. These investments are intended to deepen our pharmaceutical partnerships and to …

• We further believe these changes, supported by sustained investment in our SP-X and SR-X platforms, will enable us to defend and extend our leadership in the early-stage research and translational markets, which remain foundational to the organization.

Text added vs the prior filing · source: 10-Q · 2026-08-10

• There were no changes in our internal control over financial reporting during the six months ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than the integration of Akoya discussed below.

• As of June 30, 2026, we completed the integration of Akoya's related business processes and systems into our overall internal controls over financial reporting. We will include Akoya in our annual internal control assessment beginning with our Annual Report on Form 10-K for the year ending December …

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• As permitted under the SEC’s guidance regarding newly acquired businesses, we have elected to exclude the operations of Akoya, which we acquired on July 8, 2025, from our evaluation of internal control over financial reporting for the quarter ended March 31, 2026. Akoya represented approximately 43%…

• While we are in the process of integrating Akoya into our internal controls over financial reporting, we intend to rely on the one-year transition period allowed under the SEC's guidance, and will include Akoya in our annual internal control assessment beginning with our Form 10-K for the year endin…

• There were no changes in our internal control over financial reporting during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.